Micron Technology, Inc. vs Vir Biotechnology Inc. Common Stock — how do they compare? Micron Technology, Inc. trades at $875.61 (market cap $1.08T), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Micron Technology, Inc. is far larger — about 600× Vir Biotechnology Inc. Common Stock's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 49 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| MU | VIR | |
|---|---|---|
Market Cap | $1.08T | $1.80B |
Volume | 28,906,235 | 1,782,836 |
Sector | Technology | Health |
52-Week High | $1.21K | $11.78 |
52-Week Low | $191.94 | $5.12 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | $1.04T | $1.36B |
Dividend Yield | 0.06% | — |
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) is trading at $914.13, down 7.57% today, following strong recent performance. The stock shows robust fundamentals with a P/E of 12.82, net income margin of 63.8%, and consistent earnings beats. Technical indicators show a bullish moving average signal despite today's pullback, with support at $978. The company benefits from strong AI-driven memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus at 82.85% buy ratings and $1,590 price target. Key opportunities include sustained AI memory demand and reduced cyclicality through long-term contracts. Risks include potential growth deceleration in 2028 and market volatility. The stock's current valuation appears reasonable given strong profitability and growth trajectory.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →